Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Anti-CLL1 CAR-T cell therapy in pediatric R/R AML

Rayne Rouce • 27 May 2021
ASCO 2021
Acute Myeloid Leukemia Leukemia CAR-T

Rayne H Rouce, MD, Baylor College of Medicine, Houston, TX & Texas Children’s Hospital, Houston, TX, provides a summary of the Phase I trial (ChiCTR1900027684) of an anti-CLL1 2nd generation chimeric antigen receptor (CAR) T-cell therapy in pediatric patients with relapsed/refractory acute myeloid leukemia (AML). Whilst CAR T-cell therapy has been successful in treating B-cell malignancies, CAR T-cell-based leukemia treatment in AML are limited due to disease heterogeneity. In a cohort of 11 patients, 10 completely responded to treatment, demonstrating efficacy and safety. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Rayne Rouce

Anti CD7 CAR T-cell therapy in T-ALL
8:27
Anti CD7 CAR T-cell therapy in T-ALL
Rayne Rouce • 27 May 2021
The future of pediatric clinical trials
0:49
The future of pediatric clinical trials
Rayne Rouce • 27 May 2021

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals